XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.25.1

Stock Incentive Plans | 3 Months Ended
--- | ---
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract] |
Stock Incentive Plans | STOCK INCENTIVE PLANS Stock Options, Restricted Stock Units (“RSU”), and Performance Restricted Stock Units (“PSU”) The following table summarizes option, RSU, and PSU activity under the Company’s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan and 2019 Inducement Equity Incentive Plan, 2024 Equity Incentive Plan, and related information:
| Shares Available for Grant |  | Stock Options Outstanding |  | Weighted- Average Exercise Price |  | RSU/PSU Outstanding |  | Weighted- Average Grant Date Fair Value
Balance—December 31, 2024 | 4,559,101 |  |  | 3,409,912 |  |  | $ | 22.63 |  |  | 4,842,670 |  |  | $ | 15.38 |
Shares expired | (1,398,171) |  |  | — |  |  | — |  |  | — |  |  | — |
Common stock awards for services | (856) |  |  | — |  |  | — |  |  | — |  |  | — |
RSUs granted | (1,013,286) |  |  | — |  |  | — |  |  | 1,013,286 |  |  | 19.62 |
RSUs vested | — |  |  | — |  |  | — |  |  | (367,450) |  |  | 16.24 |
PSUs granted | (473,754) |  |  | — |  |  | — |  |  | 236,877 |  |  | 19.61 |
PSUs vested | — |  |  | — |  |  | — |  |  | (256,711) |  |  | 15.74 |
Options exercised | — |  |  | (141,050) |  |  | 21.61 |  |  | — |  |  | — |
RSUs forfeited | 10,500 |  |  | — |  |  | — |  |  | (376,425) |  |  | 13.28 |
PSUs forfeited | — |  |  | — |  |  | — |  |  | (34,937) |  |  | 18.50 |
Options forfeited | — |  |  | (72,359) |  |  | 23.83 |  |  | — |  |  | — |
Options expired | — |  |  | (252,065) |  |  | 41.48 |  |  | — |  |  | — |
Balance—March 31, 2025 | 1,683,534 |  |  | 2,944,438 |  |  | $ | 21.03 |  |  | 5,057,310 |  |  | $ | 16.47 |
The total intrinsic value of options exercised was $0.4 million and $0.1 million for the three months ended March 31, 2025 and 2024. As of March 31, 2025, the total intrinsic value of outstanding RSUs was approximately $92.7 million and there were $44.2 million of unrecognized compensation costs related to RSUs, which are expected to be recognized over a weighted-average period of 2.20 years. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of two years. The number of shares outstanding was 572,460 and 412,843 as of March 31, 2025 and 2024, respectively. The weighted-average remaining recognition period was 2.31 years and 0.84 years for the three months ended March 31, 2025 and 2024, respectively. Options outstanding that have vested and are expected to vest at March 31, 2025 are as follows:
| Number of Options Issued (In thousands) |  | Weighted-Average Exercise Price |  | Weighted-Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value (In thousands)
Vested | 1,777 |  |  | $ | 24.83 |  |  | 5.60 |  | $ | 4,226 |
Expected to vest | 1,068 |  |  | 15.11 |  |  | 8.76 |  | 6,337 |
Total | 2,845 |  |  |  |  |  |  | $ | 10,563 |
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock at March 31, 2025 for stock options that were in-the-money. The total fair value of options that vested during the three months ended March 31, 2025 was $1.2 million. As of March 31, 2025, there were approximately $9.5 million of unrecognized compensation costs related to stock options, which are expected to be recognized over a weighted-average period of 2.67 years. 2014 Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan (the “ESPP”) under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their respective earnings, provided an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately six months in length. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock on the first day of the offering period or on the exercise date. During the offering period in 2024 that ended on December 31, 2024, 66,747 shares were purchased pursuant to the ESPP for aggregate proceeds of $0.9 million from the issuance of such shares, which occurred on January 2, 2025. Valuation Assumptions The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:
|  | Three Months Ended March 31, |  |
|  | 2025 |  | 2024 |  |  |  |
Employee stock options |  |  |  |  |  |  |  |
Expected term (in years) |  | N/A |  | N/A |  |  |  |
Expected volatility |  | N/A |  | N/A |  |  |  |
Risk-free interest rate |  | N/A |  | N/A |  |  |  |
Expected dividend yield |  | N/A |  | N/A |  |  |  |
Employee stock purchase plan |  |  |  |  |  |  |  |
Expected term (in years) |  | 0.5 |  | 0.5 |  |  |  |
Expected volatility |  | 69.60% |  | 75.91% |  |  |  |
Risk-free interest rate |  | 4.23% |  | 5.38% |  |  |  |
Expected dividend yield |  | —% |  | —% |  |  |  |
Risk-free Interest Rate: The Company based the risk-free interest rate over the expected term of the award based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of grant. Volatility: The Company used an average historical stock price volatility of its own stock. Expected Term: The expected term represents the period for which the Company’s stock-based compensation awards are expected to be outstanding and is based on analyzing the vesting and contractual terms of the awards and the holders’ historical exercise patterns and termination behavior. Expected Dividends: The Company has not paid and does not anticipate paying any dividends in the near future. There were no stock options granted during the periods. Stock-Based Compensation Expense The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March 31, 2025 and 2024, included in the condensed consolidated statements of operations as follows (in thousands):
| Three Months Ended March 31, |  |
| 2025 |  | 2024 |  |  |  |
Cost of testing services | $ | 363 |  |  | $ | 457 |  |  |  |  |
Cost of product | 231 |  |  | 317 |  |  |  |  |
Cost of patient and digital solutions | 220 |  |  | 372 |  |  |  |  |
Research and development | 1,359 |  |  | 1,760 |  |  |  |  |
Sales and marketing | 2,584 |  |  | 3,044 |  |  |  |  |
General and administrative | 4,174 |  |  | 10,623 |  |  |  |  |
Total | $ | 8,931 |  |  | $ | 16,573 |  |  |  |  |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration